Daniela Weber1, Andreas Hiergeist2, Markus Weber3, Katja Dettmer4, Daniel Wolff1, Joachim Hahn1, Wolfgang Herr1, André Gessner2, Ernst Holler1. 1. Department of Hematology and Oncology, Internal Medicine III, University Medical Center, Regensburg, Germany. 2. Institute of Clinical Microbiology and Hygiene, University Medical Center, Regensburg, Germany. 3. Department of Orthopedic Surgery, University Medical Center, Regensburg, Germany. 4. Institute of Functional Genomics, University of Regensburg, Germany.
Abstract
BACKGROUND: Maintaining gastrointestinal (GI) microbiome diversity plays a key role during allogeneic stem cell transplantation (ASCT), and loss of diversity correlates with acute GI graft versus host disease (GvHD) and poor outcomes. METHODS: In this retrospective analysis of 161 ASCT patients, we used serial analyses of urinary 3-indoxyl sulfate (3-IS) levels and GI microbiome parameters within the first 10 days after ASCT to identify potential commensal microbiota-sparing antibiotics. Based on antibiotic activity, we formed 3 subgroups (Rifaximin without systemic antibiotics, Rifaximin with systemic antibiotics, and Ciprofloxacin/Metronidazole with/without systemic antibiotics). RESULTS: Mono-antibiosis with Rifaximin revealed higher 3-IS levels (P < .001), higher Clostridium cluster XIVa (CCXIVa) abundance (P = .004), and higher Shannon indices (P = .01) compared to Ciprofloxacin/Metronidazole with/without systemic antibiotics. Rifaximin followed by systemic antibiotics maintained microbiome diversity compared to Ciprofloxacin/Metronidazole with/without systemic antibiotics, as these patients showed still higher 3-IS levels (P = .04), higher CCXIVa copy numbers (P = .01), and higher Shannon indexes (P = .01). Even for this larger cohort of patients, the outcome was superior with regard to GI GvHD (P = .05) and lower transplant-related mortality (P < .001) for patients receiving Rifaximin plus systemic antibiotics compared to other types of systemic antibiotic treatment. Antibiosis with Ciprofloxacin/Metronidazole (n = 12, P = .01), Piperacillin/Tazobactam (n = 52, P = .01), Meropenem/Vancomycin (n = 16, P = .003), Ceftazidime (n = 10, P = .03), or multiple systemic antibiotics (n = 53, P = .001) showed significantly lower 3-IS levels compared to mono-antibiosis with Rifaximin (n = 14) or intravenous Vancomycin (n = 4, not statistically significant). CONCLUSIONS: Different types of antibiotic treatments show different impacts on markers of microbiome diversity. The identification of antibiotics sparing commensal bacteria remains an ongoing challenge. However, Rifaximin allowed a higher intestinal microbiome diversity, even in the presence of systemic broad-spectrum antibiotics.
BACKGROUND: Maintaining gastrointestinal (GI) microbiome diversity plays a key role during allogeneic stem cell transplantation (ASCT), and loss of diversity correlates with acute GI graft versus host disease (GvHD) and poor outcomes. METHODS: In this retrospective analysis of 161 ASCT patients, we used serial analyses of urinary 3-indoxyl sulfate (3-IS) levels and GI microbiome parameters within the first 10 days after ASCT to identify potential commensal microbiota-sparing antibiotics. Based on antibiotic activity, we formed 3 subgroups (Rifaximin without systemic antibiotics, Rifaximin with systemic antibiotics, and Ciprofloxacin/Metronidazole with/without systemic antibiotics). RESULTS: Mono-antibiosis with Rifaximin revealed higher 3-IS levels (P < .001), higher Clostridium cluster XIVa (CCXIVa) abundance (P = .004), and higher Shannon indices (P = .01) compared to Ciprofloxacin/Metronidazole with/without systemic antibiotics. Rifaximin followed by systemic antibiotics maintained microbiome diversity compared to Ciprofloxacin/Metronidazole with/without systemic antibiotics, as these patients showed still higher 3-IS levels (P = .04), higher CCXIVa copy numbers (P = .01), and higher Shannon indexes (P = .01). Even for this larger cohort of patients, the outcome was superior with regard to GI GvHD (P = .05) and lower transplant-related mortality (P < .001) for patients receiving Rifaximin plus systemic antibiotics compared to other types of systemic antibiotic treatment. Antibiosis with Ciprofloxacin/Metronidazole (n = 12, P = .01), Piperacillin/Tazobactam (n = 52, P = .01), Meropenem/Vancomycin (n = 16, P = .003), Ceftazidime (n = 10, P = .03), or multiple systemic antibiotics (n = 53, P = .001) showed significantly lower 3-IS levels compared to mono-antibiosis with Rifaximin (n = 14) or intravenous Vancomycin (n = 4, not statistically significant). CONCLUSIONS: Different types of antibiotic treatments show different impacts on markers of microbiome diversity. The identification of antibiotics sparing commensal bacteria remains an ongoing challenge. However, Rifaximin allowed a higher intestinal microbiome diversity, even in the presence of systemic broad-spectrum antibiotics.
Authors: Betty K Hamilton; Lisa A Rybicki; David Grove; Christina Ferraro; Jamie Starn; Brittany Hodgeman; Jamie Elberson; Victoria Winslow; Donna Corrigan; Aaron T Gerds; Rabi Hanna; Matt E Kalaycio; Ronald M Sobecks; Navneet S Majhail; Raed A Dweik Journal: Blood Adv Date: 2019-09-24
Authors: Jonathan U Peled; Antonio L C Gomes; Sean M Devlin; Eric R Littmann; Ying Taur; Anthony D Sung; Daniela Weber; Daigo Hashimoto; Ann E Slingerland; John B Slingerland; Molly Maloy; Annelie G Clurman; Christoph K Stein-Thoeringer; Kate A Markey; Melissa D Docampo; Marina Burgos da Silva; Niloufer Khan; André Gessner; Julia A Messina; Kristi Romero; Meagan V Lew; Amy Bush; Lauren Bohannon; Daniel G Brereton; Emily Fontana; Luigi A Amoretti; Roberta J Wright; Gabriel K Armijo; Yusuke Shono; Míriam Sanchez-Escamilla; Nerea Castillo Flores; Ana Alarcon Tomas; Richard J Lin; Lucrecia Yáñez San Segundo; Gunjan L Shah; Christina Cho; Michael Scordo; Ioannis Politikos; Kasumi Hayasaka; Yuta Hasegawa; Boglarka Gyurkocza; Doris M Ponce; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Robert R Jenq; Takanori Teshima; Nelson J Chao; Ernst Holler; Joao B Xavier; Eric G Pamer; Marcel R M van den Brink Journal: N Engl J Med Date: 2020-02-27 Impact factor: 91.245
Authors: Emma E Ilett; Mette Jørgensen; Marc Noguera-Julian; Jens Christian Nørgaard; Gedske Daugaard; Marie Helleberg; Roger Paredes; Daniel D Murray; Jens Lundgren; Cameron MacPherson; Joanne Reekie; Henrik Sengeløv Journal: Blood Adv Date: 2020-11-24
Authors: Daniel Sprockett; Natalie Fischer; Rotem Sigall Boneh; Dan Turner; Jarek Kierkus; Malgorzata Sladek; Johanna C Escher; Eytan Wine; Baruch Yerushalmi; Jorge Amil Dias; Ron Shaoul; Michal Kori; Scott B Snapper; Susan Holmes; Athos Bousvaros; Arie Levine; David A Relman Journal: Inflamm Bowel Dis Date: 2019-11-14 Impact factor: 5.325
Authors: Natasha Stephens Münch; Hsin-Yu Fang; Jonas Ingermann; H Carlo Maurer; Akanksha Anand; Victoria Kellner; Vincenz Sahm; Maria Wiethaler; Theresa Baumeister; Frederik Wein; Henrik Einwächter; Florian Bolze; Martin Klingenspor; Dirk Haller; Maria Kavanagh; Joanne Lysaght; Richard Friedman; Andrew J Dannenberg; Michael Pollak; Peter R Holt; Sureshkumar Muthupalani; James G Fox; Mark T Whary; Yoomi Lee; Tony Y Ren; Rachael Elliot; Rebecca Fitzgerald; Katja Steiger; Roland M Schmid; Timothy C Wang; Michael Quante Journal: Gastroenterology Date: 2019-04-15 Impact factor: 22.682
Authors: Sejal Morjaria; Jonas Schluter; Bradford P Taylor; Eric R Littmann; Rebecca A Carter; Emily Fontana; Jonathan U Peled; Marcel R M van den Brink; Joao B Xavier; Ying Taur Journal: Infect Immun Date: 2019-08-21 Impact factor: 3.441
Authors: Anna Cäcilia Ingham; Katrine Kielsen; Malene Skovsted Cilieborg; Ole Lund; Susan Holmes; Frank M Aarestrup; Klaus Gottlob Müller; Sünje Johanna Pamp Journal: Microbiome Date: 2019-09-13 Impact factor: 14.650